Effectiveness of Treatments That Alter Metabolomics in Cancer Patients-A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Sep 9

PMID 37686573

Authors

Santiago Navarro Ledesma

Dina Hamed-Hamed

Ana Gonzalez-Munoz

Leo Pruimboom

Affiliations

Soon will be listed here.

Abstract

Introduction: Cancer is the leading cause of death worldwide, with the most frequent being breast cancer in women, prostate cancer in men and colon cancer in both sexes. The use of metabolomics to find new biomarkers can provide knowledge about possible interventions based on the presence of oncometabolites in different cancer types.

Objectives: The primary purpose of this review is to analyze the characteristic metabolome of three of the most frequent cancer types. We further want to identify the existence and success rate of metabolomics-based intervention in patients suffering from those cancer types. Our conclusions are based on the analysis of the methodological quality of the studies.

Methods: We searched for studies that investigated the metabolomic characteristics in patients suffering from breast cancer, prostate cancer or colon cancer in clinical trials. The data were analyzed, as well as the effects of specific interventions based on identified metabolomics and one or more oncometabolites. The used databases were PubMed, Virtual Health Library, Web of Science, EBSCO and Cochrane Library. Only nine studies met the selection criteria. Study bias was analyzed using the Cochrane risk of bias tool. This systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023401474).

Results: Only nine studies about clinical trials were included in this review and show a moderate quality of evidence. Metabolomics-based interventions related with disease outcome were conflictive with no or small changes in the metabolic characteristics of the different cancer types.

Conclusions: This systematic review shows some interesting results related with metabolomics-based interventions and their effects on changes in certain cancer oncometabolites. The small number of studies we identified which fulfilled our inclusion criteria in this systematic review does not allow us to draw definitive conclusions. Nevertheless, some results can be considered as promising although further research is needed. That research must focus not only on the presence of possible oncometabolites but also on possible metabolomics-based interventions and their influence on the outcome in patients suffering from breast cancer, prostate cancer or colon cancer.

Citing Articles

Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis.

Kaur R, Gupta S, Kulshrestha S, Khandelwal V, Pandey S, Kumar A Cells. 2025; 14(1.

PMID: 39791706 PMC: 11720085. DOI: 10.3390/cells14010005.

New Metabolomic Insights Into Cancer.

Zhu J Cancer J. 2024; 30(5):301-306.

PMID: 39312449 PMC: 11424019. DOI: 10.1097/PPO.0000000000000740.

A new perspective of frozen shoulder pathology; the interplay between the brain and the immune system.

Navarro-Ledesma S, Hamed-Hamed D, Pruimboom L Front Physiol. 2024; 15:1248612.

PMID: 38617059 PMC: 11009429. DOI: 10.3389/fphys.2024.1248612.

Physical Activity, Insulin Resistance and Cancer: A Systematic Review.

Navarro-Ledesma S, Hamed-Hamed D, Gonzalez-Munoz A, Pruimboom L Cancers (Basel). 2024; 16(3).

PMID: 38339407 PMC: 10854631. DOI: 10.3390/cancers16030656.

References

Chi J, Lin P, Tolstikov V, Oyekunle T, Chen E, Bussberg V . Metabolomic effects of androgen deprivation therapy treatment for prostate cancer. Cancer Med. 2020; 9(11):3691-3702. PMC: 7286468. DOI: 10.1002/cam4.3016. View

Welch V, Petticrew M, Tugwell P, Moher D, ONeill J, Waters E . PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med. 2012; 9(10):e1001333. PMC: 3484052. DOI: 10.1371/journal.pmed.1001333. View

Yang L, Wang Y, Cai H, Wang S, Shen Y, Ke C . Application of metabolomics in the diagnosis of breast cancer: a systematic review. J Cancer. 2020; 11(9):2540-2551. PMC: 7066003. DOI: 10.7150/jca.37604. View

Leysen L, Lahousse A, Nijs J, Adriaenssens N, Mairesse O, Ivakhnov S . Prevalence and risk factors of sleep disturbances in breast cancersurvivors: systematic review and meta-analyses. Support Care Cancer. 2019; 27(12):4401-4433. DOI: 10.1007/s00520-019-04936-5. View

Zhang W, Zhang K . Quantifying the Contributions of Environmental Factors to Prostate Cancer and Detecting Risk-Related Diet Metrics and Racial Disparities. Cancer Inform. 2023; 22:11769351231168006. PMC: 10150431. DOI: 10.1177/11769351231168006. View

Mi S, Gong L, Sui Z . Friend or Foe? An Unrecognized Role of Uric Acid in Cancer Development and the Potential Anticancer Effects of Uric Acid-lowering Drugs. J Cancer. 2020; 11(17):5236-5244. PMC: 7378935. DOI: 10.7150/jca.46200. View

Wishart D . Metabolomics and the Multi-Omics View of Cancer. Metabolites. 2022; 12(2). PMC: 8880085. DOI: 10.3390/metabo12020154. View

Glunde K, Bhujwalla Z, Ronen S . Choline metabolism in malignant transformation. Nat Rev Cancer. 2011; 11(12):835-48. PMC: 4337883. DOI: 10.1038/nrc3162. View

Zarei I, Baxter B, Oppel R, Borresen E, Brown R, Ryan E . Plasma and Urine Metabolite Profiles Impacted by Increased Dietary Navy Bean Intake in Colorectal Cancer Survivors: A Randomized-Controlled Trial. Cancer Prev Res (Phila). 2020; 14(4):497-508. PMC: 8026539. DOI: 10.1158/1940-6207.CAPR-20-0270. View

10.

Czerwinska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A . Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives. Molecules. 2020; 25(7). PMC: 7181060. DOI: 10.3390/molecules25071743. View

11.

Reglero C, Reglero G . Precision Nutrition and Cancer Relapse Prevention: A Systematic Literature Review. Nutrients. 2019; 11(11). PMC: 6893579. DOI: 10.3390/nu11112799. View

12.

Ni Y, Xie G, Jia W . Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014; 13(9):3857-70. DOI: 10.1021/pr500443c. View

13.

Akinyele O, Wallace H . Understanding the Polyamine and mTOR Pathway Interaction in Breast Cancer Cell Growth. Med Sci (Basel). 2022; 10(3). PMC: 9504347. DOI: 10.3390/medsci10030051. View

14.

Tian J, Xue W, Yin H, Zhang N, Zhou J, Long Z . Differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis. Onco Targets Ther. 2020; 13:6093-6108. PMC: 7323803. DOI: 10.2147/OTT.S247393. View

15.

Wanders D, Hobson K, Ji X . Methionine Restriction and Cancer Biology. Nutrients. 2020; 12(3). PMC: 7146589. DOI: 10.3390/nu12030684. View

16.

Salaverry O . [Cancer etymology and its historical curious course]. Rev Peru Med Exp Salud Publica. 2013; 30(1):137-41. DOI: 10.1590/s1726-46342013000100026. View

17.

Feng L, Wolff B, Lukkahatai N, Espina A, Saligan L . Exploratory Investigation of Early Biomarkers for Chronic Fatigue in Prostate Cancer Patients Following Radiation Therapy. Cancer Nurs. 2016; 40(3):184-193. PMC: 5075275. DOI: 10.1097/NCC.0000000000000381. View

18.

Salas D, Peiro R . [Evidence on the prevention of cancer]. Rev Esp Sanid Penit. 2013; 15(2):66-75. DOI: 10.4321/S1575-06202013000200005. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Koopaie M, Kolahdooz S, Fatahzadeh M, Manifar S . Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta-analysis. Cancer Med. 2022; 11(13):2644-2661. PMC: 9249990. DOI: 10.1002/cam4.4640. View